Citadel Advisors’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $103M | Buy |
173,400
+104,900
| +153% | +$52.2M | 0.02% | 786 |
|
|
2025
Q4 | $33.4M | Sell |
68,500
-40,400
| -37% | -$18.8M | 0.01% | 1806 |
|
|
2025
Q3 | $45.7M | Buy |
108,900
+81,600
| +299% | +$27.4M | 0.01% | 1478 |
|
|
2025
Q2 | $7.84M | Buy |
27,300
+4,200
| +18% | +$1.26M | ﹤0.01% | 3381 |
|
|
2025
Q1 | $7.12M | Buy |
23,100
+2,800
| +14% | +$960K | ﹤0.01% | 3346 |
|
|
2024
Q4 | $7.16M | Sell |
20,300
-9,200
| -31% | -$3.38M | ﹤0.01% | 3412 |
|
|
2024
Q3 | $10.6M | Sell |
29,500
-2,300
| -7% | -$777K | ﹤0.01% | 2813 |
|
|
2024
Q2 | $10.1M | Sell |
31,800
-8,900
| -22% | -$2.36M | ﹤0.01% | 2751 |
|
|
2024
Q1 | $9.35M | Buy |
40,700
+7,400
| +22% | +$1.67M | ﹤0.01% | 3029 |
|
|
2023
Q4 | $7.32M | Buy |
33,300
+25,800
| +344% | +$5.95M | ﹤0.01% | 3254 |
|
|
2023
Q3 | $1.69M | Buy |
7,500
+800
| +12% | +$184K | ﹤0.01% | 5525 |
|
|
2023
Q2 | $1.48M | Sell |
6,700
-10,700
| -61% | -$2.37M | ﹤0.01% | 5703 |
|
|
2023
Q1 | $3.9M | Sell |
17,400
-17,100
| -50% | -$4.22M | ﹤0.01% | 4215 |
|
|
2022
Q4 | $9.59M | Sell |
34,500
-58,900
| -63% | -$14.9M | ﹤0.01% | 2900 |
|
|
2022
Q3 | $19.6M | Buy |
93,400
+62,400
| +201% | +$14M | ﹤0.01% | 1896 |
|
|
2022
Q2 | $7.3M | Sell |
31,000
-49,500
| -61% | -$10.1M | ﹤0.01% | 3126 |
|
|
2022
Q1 | $14.4M | Buy |
80,500
+19,100
| +31% | +$3.64M | ﹤0.01% | 2416 |
|
|
2021
Q4 | $13.3M | Buy |
61,400
+14,500
| +31% | +$2.85M | ﹤0.01% | 2605 |
|
|
2021
Q3 | $8.66M | Sell |
46,900
-21,700
| -32% | -$4.27M | ﹤0.01% | 3330 |
|
|
2021
Q2 | $12.3M | Sell |
68,600
-18,200
| -21% | -$3.47M | ﹤0.01% | 2764 |
|
|
2021
Q1 | $14.5M | Buy |
86,800
+49,000
| +130% | +$8.17M | ﹤0.01% | 2414 |
|
|
2020
Q4 | $5.74M | Sell |
37,800
-6,000
| -14% | -$787K | ﹤0.01% | 3458 |
|
|
2020
Q3 | $4.42M | Buy |
43,800
+5,700
| +15% | +$625K | ﹤0.01% | 3331 |
|
|
2020
Q2 | $4.61M | Sell |
38,100
-11,700
| -23% | -$1.32M | ﹤0.01% | 3202 |
|
|
2020
Q1 | $4.72M | Buy |
49,800
+20,400
| +69% | +$1.94M | ﹤0.01% | 2784 |
|
|
2019
Q4 | $2.59M | Sell |
29,400
-78,500
| -73% | -$6.91M | ﹤0.01% | 4008 |
|
|
2019
Q3 | $8.61M | Buy |
107,900
+15,900
| +17% | +$1.28M | ﹤0.01% | 2402 |
|
|
2019
Q2 | $7.18M | Buy |
92,000
+43,700
| +90% | +$4.09M | ﹤0.01% | 2593 |
|
|
2019
Q1 | $5.67M | Buy |
48,300
+32,500
| +206% | +$3.79M | ﹤0.01% | 2822 |
|
|
2018
Q4 | $1.72M | Sell |
15,800
-32,600
| -67% | -$3.78M | ﹤0.01% | 4389 |
|
|
2018
Q3 | $6.19M | Buy |
48,400
+20,900
| +76% | +$2.59M | ﹤0.01% | 2719 |
|
|
2018
Q2 | $3.11M | Sell |
27,500
-100
| -0.4% | -$11K | ﹤0.01% | 3419 |
|
|
2018
Q1 | $3.1M | Sell |
27,600
-4,500
| -14% | -$572K | ﹤0.01% | 3100 |
|
|
2017
Q4 | $4.75M | Buy |
32,100
+3,700
| +13% | +$470K | ﹤0.01% | 2533 |
|
|
2017
Q3 | $3.33M | Buy |
28,400
+1,200
| +4% | +$153K | ﹤0.01% | 2772 |
|
|
2017
Q2 | $3.53M | Buy |
27,200
+10,200
| +60% | +$1.27M | ﹤0.01% | 2495 |
|
|
2017
Q1 | $2.3M | Sell |
17,000
-2,800
| -14% | -$424K | ﹤0.01% | 2916 |
|
|
2016
Q4 | $2.84M | Sell |
19,800
-4,800
| -20% | -$613K | ﹤0.01% | 2552 |
|
|
2016
Q3 | $2.9M | Buy |
24,600
+3,400
| +16% | +$409K | ﹤0.01% | 2535 |
|
|
2016
Q2 | $2.25M | Sell |
21,200
-17,200
| -45% | -$1.92M | ﹤0.01% | 2627 |
|
|
2016
Q1 | $4.28M | Sell |
38,400
-6,000
| -14% | -$759K | 0.01% | 1904 |
|
|
2015
Q4 | $6.95M | Sell |
44,400
-2,800
| -6% | -$408K | 0.01% | 1537 |
|
|
2015
Q3 | $6.2M | Buy |
47,200
+2,000
| +4% | +$321K | 0.01% | 1724 |
|
|
2015
Q2 | $7.86M | Sell |
45,200
-42,400
| -48% | -$7.63M | 0.01% | 1643 |
|
|
2015
Q1 | $15.1M | Buy |
87,600
+55,400
| +172% | +$8.45M | 0.01% | 1150 |
|
|
2014
Q4 | $4.17M | Sell |
32,200
-27,700
| -46% | -$3.57M | ﹤0.01% | 2147 |
|
|
2014
Q3 | $7.71M | Buy |
59,900
+26,000
| +77% | +$2.68M | 0.01% | 1584 |
|
|
2014
Q2 | $3M | Buy |
33,900
+15,700
| +86% | +$1.51M | ﹤0.01% | 2335 |
|
|
2014
Q1 | $1.71M | Sell |
18,200
-3,100
| -15% | -$317K | ﹤0.01% | 2819 |
|
|
2013
Q4 | $2.41M | Buy |
21,300
+5,100
| +31% | +$460K | ﹤0.01% | 2357 |
|
|
2013
Q3 | $1.28M | Sell |
16,200
-1,300
| -7% | -$95K | ﹤0.01% | 2850 |
|
|
2013
Q2 | $1.15M | Buy |
+17,500
| New | +$1.13M | ﹤0.01% | 3042 |
|
Other funds holding UTHR
ACA
VPM
VCM
Citadel Advisors's UTHR Position: Q1 2026 in Review
Citadel Advisors increased its United Therapeutics (UTHR) stake by 93% in Q1 2026, buying an estimated $86.4M and bringing the position to 360,643 shares worth $214M. The position accounts for 0.03% of the portfolio, ranked #433.
Citadel Advisors first reported a position in UTHR in Q2 2013 and has held it in 50 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.
- Citadel Advisors held 360,643 shares of United Therapeutics worth $214M as of Q1 2026.
- Citadel Advisors bought 173,479 United Therapeutics shares in Q1 2026, an estimated $86.4M.
- United Therapeutics made up 0.03% of Citadel Advisors's portfolio in Q1 2026, its #433 holding.
- Citadel Advisors first reported a position in United Therapeutics in Q2 2013 and has held it in 50 quarters since.
- 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.